Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study

dc.contributor.author	Richarz, U.
dc.contributor.author	Fizazi, K.
dc.contributor.author	Leitz, G.
dc.contributor.author	Hu, P.
dc.contributor.author	Chi, K. N.
dc.contributor.author	Baciarello, G.
dc.contributor.author	ÖZGÜROĞLU, Mustafa
dc.contributor.author	Mundle, S. D.
dc.date.accessioned	2021-03-02T17:07:10Z
dc.date.available	2021-03-02T17:07:10Z
dc.identifier.citation	Baciarello G., ÖZGÜROĞLU M., Mundle S. D. , Leitz G., Richarz U., Hu P., Chi K. N. , Fizazi K., "Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study", ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31
dc.identifier.other	vv_1032021
dc.identifier.other	av_dcd78cb5-7273-453c-81fb-199a8d1d2d8d
dc.identifier.uri	http://hdl.handle.net/20.500.12627/3580
dc.identifier.uri	https://doi.org/10.1016/j.annonc.2020.08.910
dc.language.iso	eng
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Klinik Tıp (MED)
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study
dc.type	Bildiri
dc.contributor.department	UNICANCER , ,
dc.identifier.volume	31
dc.contributor.firstauthorID	2286552

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.